Pulmatrix (PULM)
NASDAQ:PULM
Want to see PULM full AI Analyst Report?
PULM Stock Chart & Stats
$2.35
-$0.25(-3.99%)
At close: 4:00 PM EST
$2.35
-$0.25(-3.99%)
Day’s Range― - ―
52-Week Range$1.16 - $9.37
Previous CloseN/A
Volume31.27K
Average Volume (3M)7.19K
Market Cap
$4.74M
Enterprise Value$649.38K
Total Cash (Recent Filing)$4.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-19.68
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetPulmatrix reporting zero total debt materially reduces near-term bankruptcy and interest-rate risk and preserves strategic flexibility. A debt-free capital structure gives management optionality to execute mergers, raise equity, or redirect cash toward clinical milestones without fixed debt servicing obligations.
Improving Cash BurnOperating cash outflows have meaningfully narrowed versus prior years, signaling better expense control or program prioritization. This sustained improvement reduces near-term funding urgency, extends runway for clinical work, and lowers the recurring financing burden versus earlier heavier cash burn levels.
Strategic Merger And FinancingsThe planned Eos SENOLYTIX merger is a structural business pivot that brings significant pro forma financing, new leadership and an AI-driven MitoXcel peptide platform. This transforms Pulmatrix into a gerotherapeutics play with stronger capital backing and a clearer strategic direction for pipeline advancement.
Bears Say
Collapse In RevenueRevenue falling to effectively zero is a durable red flag: it indicates the company is not generating commercial receipts to fund operations and shifts reliance onto financings or transactions. Absent sustained revenue or partner monetization, long-term self-sustainability remains unlikely within the 2–6 month horizon.
Persistent Negative Cash FlowDespite improvement, operating and free cash flow remain negative, forcing repeated capital raises. Chronic negative cash generation constrains R&D scale-up, increases dilution risk, and makes program continuity contingent on external financing or successful merger execution rather than internal cash generation.
Deal Execution And Regulatory RiskA prior merger termination demonstrates tangible execution and regulatory vulnerability for strategic transactions. That history raises the probability of further delays or failed integrations, and combined with a near-total ownership transfer in the new deal, creates governance and integration risks that can disrupt clinical and commercial plans.
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.16 and its highest was $9.37 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $4.74M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Aug 12, 2026 which is in 95 days.
How were Pulmatrix’s earnings last quarter?
Currently, no data Available
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.81% Mutual Funds
0.56% Other Institutional Investors
96.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---